12 April 2021 - Xolair for self-injection offers health care providers and appropriate patients another administration option for more flexibility in managing their treatment.

Genentech today announced that the U.S. FDA has approved the company’s supplemental biologics license application for Xolair (omalizumab) pre-filled syringe for self-injection across all approved U.S. indications. 

Xolair is the only FDA approved biologic designed to target and block immunoglobulin E for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria and nasal polyps.

Read Genentech press release